Knight Therapeutics Inc. Secures $50 Million Credit Facility for Strategic Growth and Acquisitions
- Knight Therapeutics secured a US$50 million revolving credit facility from NBC for growth in Latin America and Canada.
- The company has drawn C$60 million to finance its acquisition of Paladin, enhancing its product portfolio.
- The credit facility will support future acquisitions and strengthen Knight’s operational capabilities and financial health.
Knight Therapeutics Expands Financial Flexibility with New Credit Facility
Knight Therapeutics Inc., a Montreal-based specialty pharmaceutical company, has recently announced the establishment of a US$50 million revolving credit facility with the National Bank of Canada (NBC). This significant move, made public on June 17, 2025, is aimed at bolstering the company's growth strategy, particularly in the Latin American and Canadian markets. Knight has already drawn C$60 million from this facility to partially finance its acquisition of Paladin, marking a strategic step in its ongoing pursuit of expanding its product portfolio and market presence.
The credit facility, secured with an initial term of three years, offers Knight the flexibility to access funds for working capital and various corporate needs. NBC plans to increase the facility's limit to US$100 million and introduce an additional US$50 million accordion feature within the next six months, providing even greater financial support for Knight's operational ambitions. The ability to draw funds in both USD and CAD, coupled with interest rates tied to the SOFR or CORRA rates plus a margin, ensures that Knight can optimize its capital structure while maintaining financial agility. CFO Arvind Utchanah expresses confidence that this partnership with NBC will not only facilitate essential funding for business growth but also enhance Knight’s overall financial health.
Samira Sakhia, President and CEO of Knight, underscores the importance of this credit facility in strengthening the company’s operational capabilities. She highlights that the financial flexibility it provides will enable Knight to pursue additional acquisitions and support its mission of developing and commercializing innovative pharmaceutical products. This development reflects Knight's commitment to expanding its footprint in the pharmaceutical industry while ensuring it is well-prepared to respond to market opportunities and challenges.
In related news, Knight Therapeutics continues to focus on its strategic initiatives aimed at enhancing its competitive edge. The company remains dedicated to building partnerships and exploring new markets, which aligns with its long-term growth objectives in the specialty pharmaceutical sector. As Knight navigates this evolving landscape, the new credit facility positions it advantageously for future developments.
Overall, the establishment of the credit facility marks a pivotal moment for Knight Therapeutics, reinforcing its financial foundation and setting the stage for continued growth in the pharmaceutical market.
